Mevidalen Alzheimer’s Trial Fails: Lilly Dopamine Drug Shows No Benefit in Phase 2
Lilly's dopamine D1 modulator mevidalen missed its Phase 2 goal in 304 people with Alzheimer's at CTAD 2026. Full results, blood pressure signal and what it means for treatment.
